ORTEXORTEX News
Tracking BEN? Get live short interest, options flow, and signals on ORTEX.Sign up free →
BE
Earnings PreviewBEN

Franklin Resources Heads Into Q3 Print With Bears in Retreat

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 27 Jul 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Franklin Resources reports fiscal Q3 results on July 30 with short sellers quietly stepping back and options traders showing little urgency in either direction — a notably calm setup for a stock that has been under persistent structural pressure.

The short side has eased meaningfully. Short interest dropped roughly 15% from its late-June peak of nearly 23 million shares to around 19.5 million, now representing 3.7% of the free float. That move unwound what looked like a brief conviction build through mid-June. The borrow market confirms the retreat: cost to borrow is running at just 0.52%, a low reading that has edged down over the past month. Availability has swung sharply looser, rising to over 1,000% — meaning roughly ten shares are available to lend for every one currently borrowed — up from around 437% in late June. The lending market is not sending a bearish signal heading into the print. Options positioning reinforces that read: the put/call ratio is 0.48, fractionally below its 20-day average of 0.49, and the z-score of -0.69 places it in neutral territory. There is no detectable rush to hedge into the number.

The analyst debate has a clear tilt. Most of the Street has been lifting targets in recent weeks, with Barclays raising to $34 on July 14 and Evercore ISI following suit with a move to $35 — though both retained cautious ratings (Equal-Weight and Underperform respectively). Morgan Stanley upgraded the stock from Underweight to Equal-Weight back in May and has since nudged its target higher. TD Cowen, the lone Buy on the panel, holds a $40 target — well above where the stock now trades at $32.49. The consensus price target sits at $34.45, implying modest upside, and the stock's trailing P/E near 10.9x and EV/EBITDA of 7.4x mark it as cheaply valued relative to peers like BLK and BX, both of which have outperformed BEN in the past month. Factor scores add nuance: EPS momentum ranks in the 78th-82nd percentile across 30- and 90-day windows, a genuine positive, while EPS surprise and forward growth scores sit in the mid-40s — decent but not exceptional.

Ownership structure is unusually concentrated. The Johnson family collectively controls well over 40% of shares outstanding, with Rupert Johnson at 20% and Charles Johnson near 19%. That level of insider grip limits the float and tends to dampen volatility around events. Institutional changes at the margin have been incremental — BlackRock added around 273,000 shares at June 30, State Street added modestly — with no large active manager making a striking directional move. The most recent insider data, now over seven months old, showed cluster selling in December 2025 at prices near $22, a level the stock has since cleared decisively.

The April print provided some optimism: the stock gained 6.8% the following day and extended to a 10.5% gain over the subsequent five days. The July 30 report is a test of whether the short-side retreat and the recent run of target upgrades have correctly anticipated a continued stabilisation in assets under management — or whether the structural headwinds of active-to-passive rotation remain as durable as the bears who held through June insisted.

Stocks in this article

See the live data behind this article on ORTEX.

Open BEN on ORTEX →

How this article was generated

Generated
27 Jul 2026, 04:08
Data as of
27 Jul 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.